Mind the Gap: 
Reporting and Analysis of Sex and Gender in Health Research in Australia, a Cross-Sectional Study

Lea Merone,1,* Komla Tsey,2 Darren Russell,3 and Cate Nagle1

Abstract
Introduction: Historically, medical studies have underrepresented female participants and most research data have been collected from males and generalized to other genders. This article aims to determine if there is a sex and/or gender gap in recent Australian health research.

Methods: This descriptive cross-sectional study of the published literature examines recent Australian-based clinical trials for inclusion of sex and gender. Medians and interquartile ranges (IQRs) were calculated for study sample sizes and female:male representation. Proportion of sex and/or gender was analyzed by the clinical specialty of the trials. t-Tests were used to ascertain significance of any difference in recruitment of female and males.

Results: A total of 88 articles were included in the analysis. Most studies (n = 63) were randomized clinical controlled trials. Overall women constituted 55% (IQR 30% of all participants). Of the 71 mixed-sex studies, only 8.9% (n = 7) analyzed the data by sex. Women were significantly underrepresented in cardiology and nephrology studies and overrepresented in psychiatry, care of the elderly, and orthopedic studies.

Conclusions: When analyzed by specialty, women are overrepresented in specialties considered to be female patient dominated, such as psychiatry and care of the elderly, and underrepresented in specialties such as cardiology and nephrology. The overrepresentation of women in some specialties can reinforce gender stereotypes, potentially harming women. In addition, exclusion of males from these areas of research may be of disservice to men’s health.

Keywords: medical research; sex inclusion; Feminism; health research; sex inequalities

1College of Healthcare Sciences, James Cook University, Townsville, Queensland, Australia.
2College of Arts, Society and Education, James Cook University, Smithfield, Queensland, Australia.
3Cairns Sexual Health Service, Cairns North, Queensland, Australia.

*Address correspondence to: Lea Merone, MB ChB, College of Healthcare Sciences, James Cook University, 383 Flinders Street, Townsville, QLD 4810, Australia, E-mail: lea@doctors.org.uk

© Lea Merone et al., 2022; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Historically, medical studies have shown bias against equitable female inclusion because of concerns that research may harm the female reproductive system or that the variability of menstruation may impact on the reliability of the results. This exclusion of women was further enhanced by perceptions of the male body as the norm. Consequently, most research data have been collected from cis-gendered males and generalized to females and those who are intersex, transgender, or elsewhere on the gender spectrum (respectfully referred to herein as gender nonbinary). Cis-gendered people are those who identify as the phenotypic gender they were assigned at birth. There is a call for Australian research policy to align with those in Europe and United States and increase equitability in sex and gender reporting in medical research.

It is recommended that percentages of each sex and gender recruited into clinical research be proportional to the disease-specific sex and gender prevalence. Sex refers to the biological and physiological characteristics that define humans as female, male, or intersex, while gender is a societal construct that refers to roles, activities, and behaviors, and encompasses a wide range of identities, including woman and man. Individuals with varying sexes and genders experience diseases and respond to treatments differently and consequentially, clinical research should analyze results by sex and gender.

There are significant discrepancies between the medical care of female and male patients that are likely associated with the deficiency in knowledge of disease manifestation, investigation, and management in females. Females tend to wait longer than males for a diagnosis or pain relief, and are more likely to be misdiagnosed or discharged during serious medical events. A recent systematic scoping review of evidence underpinning a sex and gender gap in the Australian and international medical literature highlighted several issues; females remain broadly underrepresented in the medical literature and when females are included adequately, sex and gender are poorly reported and insufficiently analyzed. The 2007 National Statement on Ethical Conduct in Human Research (updated in 2018) requires fair participant inclusion in Australian clinical trials. However, these guidelines do not specifically recommend sex and/or gender proportions or stipulate performing analysis of data by sex.

The aim of this article is to determine if there remains a sex and/or gender gap in contemporary Australian health research. The objectives of this study were to determine the representation of females in a sample of recently published clinical studies (both randomized controlled trials and observational studies) conducted in Australia, if results are analyzed by sex, and if there is a difference in sex representation between specialties.

Methods

This descriptive, cross-sectional study of the published peer-reviewed literature examined a sample of the recent (2019) Australian-based clinical studies. The published articles were evaluated for inclusion of sex and the gender spectrum both in the trial and in the analysis of data. This paper utilised publicly available publications and so did not require ethics approval.

Australian studies were defined as those conducted in Australia, utilizing Australian-resident participants. Multicenter trials were included, provided they were conducted in Australia. Age restriction was applied; inclusion of trials was limited to participants 18 years of age or older.

The inclusion and exclusion criteria are provided in Table 1. We excluded clinical trial protocols as there were no results to determine whether data had been analyzed by sex and/or gender. Any text that was not subject to peer review was also excluded (Fig. 1).

Owing to the large heterogeneity of studies included, we categorized trials by medical specialty, rather than by specific disease. For this reason, it was not possible to determine underrepresentation of females by disease-specific prevalence. We therefore determined that across a specialty, representation of women and men should be 50:50. Medical specialties were determined in one of two ways; if it was stated in the article, it was categorized accordingly, and when the

| Table 1. Selection Criteria |
|----------------------------|
| **Inclusion criteria** | **Exclusion criteria** |
| Published January 1, 2019 to December 31, 2019 | Clinical trial protocol without completed data |
| RCT or nonrandomized clinical trials, cohort studies, case-control studies, clinical registered trials | Nonpeer-reviewed articles |
| Hospital or community patient population | |
| Conducted in Australia | |
| Adults ≥ 18 years | Duplicate article |
| Full text not available |

RCT, randomized controlled trials.
A search for the terms “Clinical Trial” AND “Australia” AND “adult” was conducted using commonly used databases to obtain a broad sample of articles: PubMed, Medline (hosted by OVID), PsycINFO, and Science Direct (Elsevier). A search of the Australian New Zealand Clinical Trials Register (ANZCTR) was also conducted. Where a trial was listed as completed on the ANZCTR, the article was searched for on the databases listed above. All searches were limited to completed Australian studies published in 2019 as we were exclusively seeking to determine if there is a sex and/or gender gap in contemporary Australian research.

The study was guided by Arksey and O’Malley’s framework with modifications by Levac et al. Lead author (L.M.) collated studies, removed duplicates, and conducted the initial screen of articles by title and abstract. Full texts of included studies were reviewed independently by two authors (L.M. and K.T.). A data extraction form was developed to tabulate variables of interest: medical specialty, study design, sample size, proportion of females to males, and analysis by sex and/or gender. Where studies gave percentage of females and males by trial arm, an average was calculated. We calculated the median and interquartile range (IQR) for study sample sizes and female:male representation. Proportional sex and/or gender representation were then established by clinical specialty of the trial. Finally, using statistical package Stata, we performed paired t-tests where possible for representation of females and males across the mixed-sex studies that provided information on sex proportions.

**Results**

**Search results**

The database search yielded a total of 1425 records and the search of the Australian Clinical Trials Registries produced 2696 published studies. Following screening of titles and abstracts for selection criteria, a total of 88 articles were included in the analysis.

**Description of sample**

Most studies (n=63) were randomized controlled trials (RCTs). Other designs included observational studies (n=19) (of which five were cohort studies) and feasibility/safety or effectiveness trials (n=6).

The 88 studies were divided into mixed-sex (n=71) and single-sex (n=8 female only and n=1 male only) categories. There were eight studies that did not provide information on sex or gender proportions.

The 71 studies with mixed-sex participants included the following specialties: psychiatry (n=22), oncology (n=8), neurology (n=6), gerontology (n=6), pain management (pain) (n=5), cardiology (n=4), respiratory (n=4), orthopedics (n=4), endocrinology (n=2), gastroenterology (n=2), ophthalmology (n=2), nephrology (n=2), general practice (n=1), microbiology (n=1), dermatology (n=1), and complementary medicine (n=1). Of the nine single-sex studies, specialties included were oncology (n=3), obstetrics and gynecology (n=2), sexual health (n=1), gerontology (n=1), rehabilitation (n=1), and psychiatry (n=1).

**Sex and gender representation**

There were no studies that explicitly included intersex people or gender nonbinary people. There were eight studies with only female participants, three of which related to gynecological and obstetric health and one relating to each of endocrinology, psychiatry, sexual...
Of the 82 studies included in our analysis, 74 were sex-specific and 8 were single-sex studies. All study populations were recruited from Australia. All eight of these studies were specific to female biology, except for the breast cancer study. A single study examining prostate cancer recruited only male participants.

For both the mixed-sex and single-sex studies, the median overall sample size was 107.5 (IQR 291.25), and the range of participants across the studies was 7 to 250,648. The median female sample size across all studies was 55% (IQR 30%), and the median male sample across all studies was 45% (IQR 30%). Of the 79 mixed-sex studies, only 8.9% (n = 7) analyzed data by sex.

Representation of sex varied widely between specialties (Fig. 2 and Table 2). Specialties that significantly underrepresented females in Australian research were cardiology (female:male ratio 30:70, p = 0.01) and nephrology (female:male ratio 38:62, p = 0.02). Specialties that significantly overrepresented females were psychiatry (female:male ratio 67:33, p = 0.02), orthopedics (female:male ratio 68:32, p = 0.001), and care of the elderly (female:male ratio 65:35, p = 0.02).

Of the single-sex studies, three of the eight women-only studies concerned conditions from which biological males do not suffer, such as gestational diabetes and endometrial cancer. One single-sex female study, however, was related to breast cancer, which affects both females and males. The single male-only study concerned prostate cancer.

There was no clear consensus in the literature on the use of the terms “sex” and “gender.” No study recruited participants outside of the binary sexes female and male, while five studies used the term gender to refer to biological sex.

Discussion

Our analysis highlights several issues with the diversity of study populations in Australian clinical research. Several studies (n = 5) used the term gender to refer to biological sex. Other studies have found that clinical researchers often use the terms sex and gender synonymously and conflating the terms may lead to confusion about the contributions of sex and gender to health and incomplete analysis of health research data. Krieger argues that greater precision is needed when considering whether to analyze sex and/or gender (or neither) in clinical research, requiring critical thinking and an understanding of how sex and gender interact to determine which is warranted.

FIG. 2. Percentage of females:males included in 2019 Australian studies by specialty.
Sex and gender representation in health research

Our study demonstrated that in 2019, females represented approximately half of all participants in Australian health research. This finding is echoed in a large data study in the United States, which also showed a 50:50 female:male representation across all clinical trials, but significant discrepancies between clinical specialties. Adequate overall female representation across all health research is possibly indicative of the successful and relatively recent efforts to include females in clinical trials with cis-gendered people. It has been noted previously that transgender people are “invisible” in clinical research. Our study demonstrated a total absence in the explicit participation of gender nonbinary people in Australian health research. The exclusion of intersex and gender nonbinary people from clinical research may serve to further disadvantage these population subgroups in much the same way as women, leaving an uncertainty around clinical diagnosis and response to treatment. In addition, once gender nonbinary people are included in health research, subanalysis by sex and gender should be performed.

Analysis by sex and gender in health research

Analyzing by sex allows researchers to identify differences between females and males, which may be important for clinical diagnosis and management. Our findings indicate that in 2019, few studies in the Australian clinical literature analyzed their results by sex and none by gender. These findings are in keeping with other studies. DeBruin noted that when women are included in adequate numbers in clinical studies, rarely is sex-specific analysis performed to determine the effects of sex on the results.

When sex analysis is performed, it is often done without regard for advancing women’s health, such as how the disease specifically affects women or differences in treatment that may be required. Analyses of results by sex appear to be poor across all study designs and, as demonstrated by our analysis and other studies, is not improving. According to Vidaver, there were studies surrounding general health, they were exclusively about transgender people rather than inclusion in clinical trials with cis-gendered people. It has been noted previously that transgender people are “invisible” in clinical research. Our study demonstrated a total absence in the explicit participation of gender nonbinary people in Australian health research. The exclusion of intersex and gender nonbinary people from clinical research may serve to further disadvantage these population subgroups in much the same way as women, leaving an uncertainty around clinical diagnosis and response to treatment. In addition, once gender nonbinary people are included in health research, subanalysis by sex and gender should be performed.

Sex and gender representation in health research

Our study demonstrated that in 2019, females represented approximately half of all participants in Australian health research. This finding is echoed in a large data study in the United States, which also showed a 50:50 female:male representation across all clinical trials, but significant discrepancies between clinical specialties. Adequate overall female representation across all health research is possibly indicative of the successful and relatively recent efforts to include females in clinical trials with cis-gendered people. It has been noted previously that transgender people are “invisible” in clinical research. Our study demonstrated a total absence in the explicit participation of gender nonbinary people in Australian health research. The exclusion of intersex and gender nonbinary people from clinical research may serve to further disadvantage these population subgroups in much the same way as women, leaving an uncertainty around clinical diagnosis and response to treatment. In addition, once gender nonbinary people are included in health research, subanalysis by sex and gender should be performed.

Analysis by sex and gender in health research

Analyzing by sex allows researchers to identify differences between females and males, which may be important for clinical diagnosis and management. Our findings indicate that in 2019, few studies in the Australian clinical literature analyzed their results by sex and none by gender. These findings are in keeping with other studies. DeBruin noted that when women are included in adequate numbers in clinical studies, rarely is sex-specific analysis performed to determine the effects of sex on the results.

When sex analysis is performed, it is often done without regard for advancing women’s health, such as how the disease specifically affects women or differences in treatment that may be required. Analyses of results by sex appear to be poor across all study designs and, as demonstrated by our analysis and other studies, is not improving. According to Vidaver, there were studies surrounding general health, they were exclusively about transgender people rather than inclusion in clinical trials with cis-gendered people. It has been noted previously that transgender people are “invisible” in clinical research. Our study demonstrated a total absence in the explicit participation of gender nonbinary people in Australian health research. The exclusion of intersex and gender nonbinary people from clinical research may serve to further disadvantage these population subgroups in much the same way as women, leaving an uncertainty around clinical diagnosis and response to treatment. In addition, once gender nonbinary people are included in health research, subanalysis by sex and gender should be performed.
et al., inclusion of women as study subjects did not improve over a 5-year period of analysis following publication of guidelines on the inclusion of female subjects in clinical trials. More recently, Geller et al. determined that National Institute of Health (NIH) policies have not resulted in significant increases in reporting by sex (or race and ethnicity). Analysis of results by sex is important; because women’s and men’s anatomy and physiology are different, females and males may be more prone to different diseases and respond differently to treatments and interventions. The sex and gender research gap may translate into real-life impacts for female patients. For example, organ transplants in female patients are less successful than in male patients, postmenopausal women respond differently to antidepressant treatment than males, and females are diagnosed later than males with peanut allergy, despite outnumbering male allergy sufferers. While subgroup analyses can increase type 1 errors in research, females have been significantly underrepresented in previous medical research and we maintain it is important to power studies to perform sex-based analysis to aid in closing the research and medical gap between females and males.

Sex and gender representation in health research by specialty

The results presented in this cross-sectional analysis suggest that women are adequately included in clinical research overall, however, when results were analyzed by clinical specialty, females were shown to be underrepresented in the research of some medical specialties and overrepresented in others. This has been observed in a large data study in the United States, with similar discrepancies noted in cardiology and nephrology research. This 2021 analysis of sex inclusion in US trials demonstrated that in adult medicine, cardiology clinical trials had the most significant association with lower recruitment of females.

In keeping with this study, our results show that it is possibly the perceptions of sex prevalence that drive recruitment percentages of females into clinical trials, rather than sex prevalence statistics, as recommended by Mastroianni et al. in the NIH Revitalization Act (1993). It is possible that perceptions of disease prevalence are driven by what is observed in clinical practice; however, underrepresentation or overrepresentation of women in health research may alter diagnosis patterns and enhance existing perceptions that may be unfounded.

Studies have reported that the perception of disease and sex biases may be primary drivers for underrepresenting females in medical research, rather than proportion of females and males affected by the disease. Many perceptions of sex-related prevalence appear to be outdated, for example, ischemic heart disease is the leading cause of death in high-income countries in both females and males, and females experience greater functional disability, symptom burden, and higher prevalence of nonobstructive coronary artery disease than men. Melloni et al., examined the representation of females in cardiovascular disease randomized controlled trials (RCT’s).

 Twenty studies recruited only male participants compared to a single study that recruited only female participants. Importantly, female representation was higher in cardiovascular diseases that are perceived to affect females more, such as hypertension and stroke, but lower in diseases perceived to affect fewer females, such as coronary disease. Welch et al. performed a cross-sectional analysis of Canadian clinical research to ascertain the inclusion of female participants and the extent of sex-based analyses, determining that, while the gap in terms of female inclusion is not large, females are underrepresented in clinical research for some specialties and sex-based analysis is significantly underutilized.

Cardiovascular disease has historically been perceived to be a disease affecting men rather than women. However, evidence shows that in more recent times, this is not the case. In the general adult Australian population in 2018, the absolute risk for lifetime prevalence of heart disease was very similar between women and men with approximately a 1% difference; 4.2% and 5.4%, respectively. Furthermore, recent statistics from 2019 show that heart disease is increasing in younger women and that outcomes are poorer for women than for men. This may be partially due to the observed research gap.

Females with acute myocardial infarction present with different symptoms than men, are less likely to have their infarction identified during diagnostic angiography than men, and are often underinvestigated and consequently less likely to be managed correctly. The rising incidence of cardiovascular disease in young females younger than 40 years does not appear to correspond to an increase in representation in the recent research literature. The Australian Longitudinal Study on Women’s Health is helping to decrease the research gaps; however, as our analysis highlights, in general cardiology research studies, females remain underrepresented.
In high-income countries, the prevalence of chronic kidney disease is higher in women than in men, yet this is not reflected in the proportion of females recruited to nephrology research. Renal physiology is also different in females and males; females have 12% fewer glomeruli than males and female sex hormones increase the synthesis of angiotensinogen, but decrease synthesis of angiotensin-converting enzyme, both of which increase the risk of hypertension. Furthermore, in the general adult population, the lower muscle mass of females compared to males means that reference ranges for estimates of glomerular filtration rate in blood tests may be inappropriate. Despite these important differences, sex differences are neglected in nephrology research. In keeping with our findings, analysis of female participation in research by burden of disease in the United States demonstrated that, alongside oncology, neurology, and immunology, nephrology had the lowest female enrolment relative to disability-adjusted life years.

Our study suggests that research in the care of the elderly appears to be biased toward females; however, this may be owing to the longer lifespan of women; there are more elderly women than men and consequently are more likely to present to services and be recruited into trials. Despite their longer lifespan, women of all ages are more likely than men to report poor health and see their doctor; therefore, in this age group, where women often outnumber men, it is possible that there may be some selection bias when recruiting to clinical trials.

Research conducted in Canada also suggests that women report poorer health because of their longer lives and therefore greater likelihood of developing health problems. It is possible that this factor is also at play when considering the results for orthopedic studies, which included predominantly elderly patients older than 60 years; osteoporosis is related to falling estrogen levels and more common in elderly females.

The findings from this study suggest that research in psychiatry appears to also be significantly dominated by female participants, even though high numbers of both women and men are affected by psychiatric ailments. Of note, men are more likely than women to die by suicide, whereas women remain more likely to be diagnosed with an anxiety or personality disorder. The dominance of female participants in psychiatry is possibly rooted in historical perceptions of women as “hysterical.” Hysteria was the first mental health disorder that was considered a “female disease,” driven historically by perceptions of women as “weak” and “guilty” of sins or supernatural influence.

As a diagnosis, hysteria diminished in the 1970s and was deleted from the Diagnostic and Statistical Manual of Mental Disorders III (DSM III) in 1980, although it has been argued that other terms such as anxiety, borderline personality disorder, and bipolar mood disorder have come to replace this label for female patients, and these conditions have consequentially become stigmatized and potentially overdiagnosed. If this is the case, it may assist in the explanation of the sex and gender gap swung in the favor of the female participant in psychiatric research. We postulate that this may then become a self-fulfilling prophecy and enhance perceptions of women as anxious or hysterical, to the detriment of women’s health. Mental ill-health in women is frequently misunderstood, potentially leading to bias and prejudice.

Limitations
Many of the included studies used the terms sex and gender interchangeably. This lack of definition and clarity is a limitation of this study, and to mitigate this, we explored sex and/or gender representation in the published health research literature. The data collected were study results published during a single year and therefore may not be truly representative of clinical trials across Australia. The data collected were also limited to that which was published and it is possible that some of the studies analyzed results by sex and found no difference, and therefore did not include these results in their publication.

Heterogeneity across studies made analysis by disease unfeasible; therefore, we analyzed data more broadly by specialty, and assumed that the required representation of female and male participants be 50:50. This assumption was used as the basis for determining overrepresentation and underrepresentation. Finally, on subspecialty analysis, some sample sizes were small and therefore may not be an accurate representation of female inclusion.

Restricting studies to those conducted in Australia, and that utilized Australian-resident participants limited the inclusion of studies in our analysis, but by focusing on research in Australia, our findings can inform Australian public health.

Conclusion and Implications for Public Health
Overall, the inclusion of women in clinical research conducted in Australia appears balanced; however,
when analyzed by specialty, women are overrepresented in specialties perceived to be female patient dominated, such as psychiatry, and significantly underrepresented in specialties such as cardiology and nephrology. Despite increasing numbers of female participants in medical research, there is observable over-recruitment and under-recruitment of females in some clinical specialties. Overrepresentation of women in some specialties can reinforce gender stereotypes, potentially harming women. In addition, exclusion of males from these areas of research may be a disservice to men’s health. Where women are adequately represented, there is rarely gender-based analysis, and we believe this should be a requirement for publication in journals. Intersex and gender nonbinary people also remain underrepresented in general medical research.

Author Disclosure Statement
No competing financial interests exist.

Funding Information
No funding was received for this article.

References

1. Bruinvels G, Burden RJ, McGregor AJ, et al. Sport, exercise and the menstrual cycle: Where is the research? Br J Sports Med 2017;51:487–488.
2. Liu KA, Mager NA. Women's involvement in clinical trials: Historical perspective and future implications. Pharm Pract (Granada) 2016;14:708.
3. Dresser, R. Wanted Single, White Male for Medical Research. Hastings Cent Rep 1992;22:24–29. DOI: 10.2307/3562720.
4. Holdcroft A. Gender bias in research: How does it affect evidence based medicine? J R Soc Med 2020;21:57–62.e1.
5. Jacobson R, Daphna J. Self-reported gender identity and sexuality in an online sample of cisgender, transgender, and gender-diverse individuals: An exploratory study. J Sex Res 2018;55:249–263.
6. Steinberg JR, Turner BE, Weeks BT, et al. Analysis of female enrollment and participation sex by burden of disease in US clinical trials between 2000 and 2020. JAMA Netw Open 2021;4:e2113749.
7. Chen EH, Shofer FS, Dean AJ, et al. Gender disparity in aneclic treatment of emergency department patients with acute abdominal pain. Acad Emerg Med 2008;15:414–418.
8. Robertson J. Waiting Time at the Emergency Department from a Gender Equity Perspective. Gothenburg: University of Gothenburg: Institute of Medicine at the Sahlgrenska Academy, 2014.
9. Nabel EG. Coronary heart disease in women—An ounce of prevention. N Engl J Med 2000;343:572–574.
10. Merone L, Tsey K, Russell D, et al. Sex inequalities in medical research: A systematic scoping review of the literature. Women Health Rep (New Rochelle) 2021;3:9059.
11. The National Health and Medical Research Council, Australian Research Council, Universities Australia. National Statement on Ethical Conduct in Human Research 2018. Canberra: Commonwealth of Australia, 2018.
12. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems. 2016 [Cited 01/2020]. Available at: https://icd.who.int/browse10/2016/en Accessed January 1, 2020.
13. Arkes H, O'Malley L. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol 2005;8:19–32.
14. Levac D, Colquhoun H, O'Brien KK. Scoping studies: Advancing the methodology. Implement Sci 2010;5:69.
15. Sta. Sta. 14, 2022. [March 27, 2022]. Available at: https://www.stata.com/stata14/ Accessed January 1, 2020.
16. Australian Government, National Health and Medical Research Council. Australian Research Council, Department of Industry Innovation and Science. Clinical Trial Registries. 2021 [03/2020]; Available at: https://www.australianclinicaltrials.gov.au/clinical-trial-registries Accessed March 3, 2020.
17. O'Reilly S, Versace V, Mohembi M et al. The effect of a diabetes prevention program on dietary quality in women with previous gestational diabetes. BMC Womens Health 2019;19:98.
18. Callaway LK, McIntyre DH, Barrett HL, et al. Probiotics for the prevention of gestational diabetes mellitus in overweight and obese women: Findings from the SPRING double-blind randomized controlled trial. Diabetes Care 2019;42:364–371.
19. Carolan-Ohay M, Saykoh P. A randomized controlled trial of a web-based education intervention for women with gestational diabetes mellitus. Midwifery 2019;68:39–47.
20. Singleton A, Partridge SR, Raeside R, et al. A text message intervention to support women's physical and mental health after breast cancer treatments (EMPOWER-SMS): A randomised controlled trial protocol. BMC Cancer 2019;19:660.
21. Sachs B, Misrai V, Tabatabaei S, et al. Multicenter experience with photoselective vaporization of the prostate on men taking oral anticoagulants. Asian J Urol 2020;7:340–344.
22. Johnson JL, Greaves L, Repta R. Better science with sex and gender: Facilitating the use of a sex and gender-based analysis in health research. Int J Equity Health 2009;8:14.
23. Krieger N. Genders, sexes, and health: What are the connections—And why does it matter? Int J Epidemiol 2003;32:652–657.
24. Ramsay L. Participation of Women in Clinical Trials Increasing Due to Gender-based Drugs 2019 [February 13, 2021]. Available at: https://www .centerwatch.com/articles/24573-participation-of-women-in-clinical-trials-increasing-due-to-gender-based-drugs Accessed February 13, 2021.
25. Jones T. Intersex studies: A systematic review of the International health literature. SAGE Open 2018:1–22. DOI: 10.1177/25824017745577.
26. Intersex Human Rights Australia. Intersex population figures. 2013 [January 1, 2020]. Available at: https://ihra.org.au/16601/intersex-numbers/ Accessed January 16, 2020.
27. Australian Bureau of Statistics. Census of Population and Housing: Reflecting Australia 2016 [January 1, 2020]. Available at: https://www.abs .gov.au/ausstats/abs@.nsf/Lookup/bySubject/20710.0 ~ Main Features ~ Sex and Gender Diversity in the 2016 Census ~ 100 Accessed January 15, 2020.
28. Marshall Z, Welch V, Minichielo A, et al. Documenting research with transgender, nonbinary, and other gender diverse (trans) individuals and communities: Introducing the global trans research evidence map. Transgend Health 2019;4:68–80.
29. Chan PS. Invisible gender in medical research. Circ Cardiovasc Qual Outcomes 2019;12:e005694.
30. Welch V, Doul M, Yoganathan M et al. Reporting of sex and gender in randomized controlled trials in Canada: A cross-sectional methods study. Res Integr Peer Rev 2017;2:15.
31. DeBruin D. Justice and the Inclusion of Women in Clinical Studies: A Conceptual Framework. Washington DC: National Academies Press, 1999.
32. Mansukhani NA, Yoon DY, Teter KA, et al. Determining if sex bias exists in human surgical clinical research. JAMA Surg 2016;151:1022–1030.
33. Yoon DY, Mansukhani NA, Stubbs VC, et al. Sex bias exists in basic science and translational surgical research. Surgery 2014;156:508–516.
34. Vidaver RM, Mansukhani NA, Stubbs VC, et al. Women subjects in NIH-funded clinical research literature: Lack of progress in both representation and analysis by sex. J Womens Health Gend Based Med 2000;9:495–504.
35. Keller SE, Koch AR, Roesch P, et al. The more things change, the more they stay the same: A study to evaluate compliance with inclusion and assessment of women and minorities in randomized controlled trials. Acad Med 2018;93:630–635.
36. Barajas-Martinez A, Ibarra-Coronado E, Sierra-Vargas MP, et al. Sex differences in the physiological network of young subjects. Front Physiol 2021;12:678507.
37. Ortone EP, Pierdominici M, Rider V. Sex hormones and gender differences in immune responses. Front Immunol 2019;10:1076.
40. Marrocco J. Sex in the brain: Hormones and sex differences. Dialogues Clin Neurosci 2016;18:373–383.
41. Merone L, Tsey K, Russell D, et al. Representation of Women and Women’s Health in Australian Medical School Course Outlines, Curriculum Requirements and Selected Core Clinical Textbooks. Australia: James Cook University, 2022.
42. Puoti F, Ricci A, Nanni-Costa A, et al. Organ transplantation and gender differences: A paradigmatic example of intertwining between biological and sociocultural determinants. Biol Sex Differ 2016;7:35.
43. Sramek JM, Murphy MF, Cutler NR. Differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci 2016;18:447–457.
44. Institute of Medicine (US) Board on Population and Public Health Practice. Why Sex-Specific Reporting is Important—Sex-Specific Reporting of Scientific Research. Washington DC: National Academies Press, 2012.
45. Tannou J, van der Tweel I, Teerenstra S, et al. Subgroup analyses in confirmatory clinical trials: Time to be specific about their purposes. BMC Res Methodol 2016;16:20.
46. Moller-Leimkuhler A. Gender difference in cardiovascular disease and comorbid depression. Dialogues Clin Neurosci 2007;9:71–83.
47. Eaton NR, Keyes KM, Kreuger RF, et al. An invariant dimensional liability model of gender differences in mental disorder prevalence: Evidence from a national sample. J Abnorm Psychol 2011;121:282–288.
48. Mastroiani AC, Faden R, Federman D. NIH Revitalization Act of 1993 Public Law 103-43. Washington DC: National Academies Press, 1994.
49. Merone L, Tsey K, Russell D, et al. Sex and gender gaps in medicine and the androcentric history of medical research. Austr N Z J Public Health 2021;45:424–426.
50. Feldman S, Ammar W, Lo K, et al. Quantifying sex bias in clinical studies at scale with automated data extraction. JAMA Netw Open 2019;2:e196700.
51. Yahagi K, Davis HR, Arbustini E, et al. Sex differences in coronary artery disease: Pathological observations. Atherosclerosis 2015;239:260–267.
52. Kothawade K, Bairey Merz CN. Microvascular coronary dysfunction in women—Pathophysiology, diagnosis, and management. Curr Probl Cardiol 2011;36:291–318.
53. Melloni C, Berger JS, Wang TY, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010;3:135–142.
54. Merz CN. The Yentl syndrome is alive and well. Eur Heart J 2011;32:1313–1315.
55. Vogel BA, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease commission: Reducing the global burden by 2030. Lancet 2021;397:2385–2438.
56. Woodward M. Cardiovascular disease and the female disadvantage. Int J Environ Res Public Health 2019;16:1165.
57. Australian Bureau of Statistics. National Health Survey: First Results 2017–2018. 2018 [March 1, 2020]. Available at: https://www.abs.gov.au/EnvironResPublicHealth2019;16:1165.
58. Vaccarino V, Parsons L, Every NR, et al. Sex-based differences in early outcomes for men and women with ST-elevation myocardial infarction. Circulation 2019;139:1047–1056.
59. Khan E, Brierer D, Amerena J, et al. Differences in management and outcomes for men and women with ST-elevation myocardial infarction. Med J Aust 2018;209:118–123.
60. Gudnadottir GS, Anderson K, Thrainsdottir IS, et al. Gender differences in coronary angiography, subsequent interventions and outcomes among patients with acute coronary syndromes. Am J Heart 2017;191:65–74.
61. Daly CC, Lopez F, Sendon JL, et al. Gender differences in the management and clinical outcome of stable angina. Circulation 2006;113:490–496.
62. Regitz-Zagrosek V. Sex and gender differences in health. Science & Society Series on Sex and Science. EMBO Rep 2012;13:596–603.
63. Women’s Health Australia. The Australian Longitudinal Study on Women’s Health. 2021 [November 25, 2021]. Available at: https://alswh.org.au/outcomes/publications/wwpg-28?swquery=cardiovascular&yr Accessed September 25, 2021.
64. Carrero JJ, Hecking M, Ulassi I, et al. Chronic kidney disease, gender, and access to care: A global perspective. Semin Nephrol 2017;37:296–308.
65. Maimonides R. Low nephron number and its clinical consequences. Med J 2011;2:e0061.
66. Cobo G, Hekcing M, Port FK, et al. Sex and gender differences in chronic kidney disease: Progression to end-stage renal disease and haemodialysis. Clin Sci (Lond) 2016;130:1147–1163.
67. Women’s health and kidney disease. Nat Rev Nephrol 2018;14:139.
68. Luy M, Minagawa Y. Gender gaps—Life expectancy and proportion of life in poor health. Health Rep 2014;25:12–19.
69. Curtis JR, Safford MM. Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging 2012;29:549–564.
70. Department of Health. Prevalence of mental disorders in the Australian population. 2009 [June 1, 2020]. Available at: https://www1.health.gov.au/internet/publications/publishing.nsf/Content/mental-pubs-m-mhausst2-toc~mental-pubs-m-mhausst2-hig~mental-pubs-m-mhausst2-hig-pre Accessed January 16, 2020.
71. Jackson G. Pain and Prejudice. Australia: Allen & Unwin, 2019.
72. Tasca C, Rapetti M, Giovanni Carta M, et al. Women and hysteria in the history of mental health. Clin Pract Epidemiol Ment Health 2012;8:110–119.
73. Swartz S. Feminism and psychiatric diagnosis: Reflections of a feminist practitioner. Fem Psychol 2013;23:41–48.

Cite this article as: Merone L, Tsey K, Russell D, Nagle C (2022) Mind the gap: reporting and analysis of sex and gender in health research in Australia, a cross-sectional study. Women’s Health Report 3:1, 759–767, DOI: 10.1089/whr.2022.0033.

Abbreviations Used

DSM III = Diagnostic and Statistical Manual of Mental Disorders III
ICD = International Statistical Classification of Diseases
IQR = interquartile range
RCT = randomized controlled trial
SD = standard deviation

Publish in Women’s Health Reports

- Immediate, unrestricted online access
- Rigorous peer review
- Compliance with open access mandates
- Authors retain copyright
- Highly indexed
- Targeted email marketing

liebertpub.com/whr